An FDA advisory panel endorsed Grail’s Galleri blood test for multiple cancers after voting that benefits outweigh risks, marking an important step for early detection of disease before symptoms appear. The panel unanimously supported safety, but effectiveness votes split, reflecting ongoing uncertainty around clinical value versus false positives and downstream follow-up. The vote outcome matters because the FDA typically weighs advisory committee input heavily even though the decision is not binding. Galleri is designed for adults age 50 and over, and prior published evidence in Nature Medicine reported cancer signals in 287 participants, with specificity framed as high, while emphasizing that a negative test does not rule out cancer. The next regulatory stage is likely to focus on the magnitude of benefit—particularly whether earlier detection reduces advanced disease and cancer mortality.